DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Atomi Financial Group Inc.

Atomi Financial Group Inc. lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.5% during the fourth quarter, Holdings Channel reports. The fund owned 5,374 shares of the medical device company’s stock after acquiring an additional 1,438 shares during the period. Atomi Financial Group Inc.’s holdings in DexCom were worth $418,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Versant Capital Management Inc purchased a new stake in DexCom during the 4th quarter worth about $25,000. Riverview Trust Co grew its position in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in shares of DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after buying an additional 265 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in DexCom in the third quarter valued at approximately $57,000. Finally, Covestor Ltd lifted its stake in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after acquiring an additional 335 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Up 1.2 %

DXCM opened at $88.75 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business has a 50 day moving average price of $79.25 and a two-hundred day moving average price of $77.51. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market cap of $34.67 billion, a PE ratio of 53.14, a P/E/G ratio of 2.23 and a beta of 1.12.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on DXCM. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company raised their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Royal Bank of Canada cut their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. upped their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.